US 10117907
Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
granted A61KA61K38/1709A61K38/2278
Quick answer
US patent 10117907 (Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases) held by Arizona Board of Regents on Behalf of the University of Arizona, a body corporate expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
- Grant date
- Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K38/1709, A61K38/2278, A61P, A61P25/02